Remdesivir (Veklury)

CADTH recommends that Veklury should be reimbursed by public drug plans for the treatment of COVID-19 in hospitalized patients 12 years of age and older (weighing at least 40 kg) with pneumonia requiring supplemental oxygen if certain conditions are met. Veklury should only be covered when initiated in hospitalized patients aged 12 years and older and weighing at least 40 kg with confirmed COVID-19 and requiring additional oxygen due to COVID-19 but not ventilation. Veklury should not be covered when initiated in patients receiving artificial life support who cannot breathe on their own or in hospitalized patients who do not require oxygen support. Veklury should only be reimbursed if the treatment duration is 5 days and the cost is reduced.